FDA Output, July 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in July 2026. Updated July 30.
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in July 2026. Updated July 30.
The Innovation Nexus program created by the American Urological Association in 2023 is an innovation ecosystem that connects entrepreneurs, clinicians, investors, and industry partners in mentoring relationships that are mutually beneficial. It’s perhaps one reason why urology is, surprisingly, a hot area of investment right now.
CMS reiterates its plan to cancel the streamlined path. Excerpted from Pathways’ Picks June 8: MDUFA Agreement, Medicare Plans, EU Parliament Response, and More.